Preliminary Results of a Retrospective Study on a Regimen Based on Orelabrutinib Combined with Anti-CD20 Monoclonal Antibody in Patients with Marginal Zone Lymphoma

被引：0
|
作者：
Peng, Hongling [1 ]
Xiang, Xixi [2 ]
Rao, Jun [2 ]
Yan, Wenzhe [1 ]
Cui, Yajuan [1 ]
Li, Ji [1 ]
Jiang, Yafeng [1 ]
Zhang, Xi [1 ,2 ]
机构：
[1] Cent South Univ, Xiangya Hosp 2, Dept Hematol, Changsha, Peoples R China
[2] Army Med Univ, Xinqiao Hosp, Med Ctr Hematol, State Key Lab Trauma & Chem Poisoning,Chongqing K, Chongqing, Peoples R China
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-203787
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：6293 / 6293
页数：1
相关论文
共 50 条
  • [1] Phase II trial evaluating the efficacy and safety of the anti-CD20 monoclonal antibody obinutuzumab in patients with marginal zone lymphoma
    Grunenberg, Alexander
    Kaiser, Lisa M.
    Woelfle, Stephanie
    Schmelzle, Birgit
    Viardot, Andreas
    Moeller, Peter
    Barth, Thomas F. E.
    Muche, Rainer
    Dreyhaupt, Jens
    Buske, Christian
    FUTURE ONCOLOGY, 2020, 16 (13) : 817 - 825
  • [2] Treatment of Ocular Adnexal Lymphoma with Intralesional Injection of Anti-CD20 Monoclonal Antibody: Preliminary Results
    Modorati, G.
    Colucci, A.
    Miserocchi, E.
    Berchicci, L.
    Govi, S.
    Ferreri, A.
    Bandello, F.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2010, 51 (13)
  • [3] Anti-CD20 monoclonal antibody (Rituximab) in gastric extranodal marginal zone (MALT) non-Hodgkin's lymphoma (NHL) patients: Clinical and biological results (Phase II study).
    Martinelli, G
    Laszlo, D
    Conconi, A
    Rabascio, C
    Ferreri, AJ
    Pruneri, G
    Crosta, C
    Ponzoni, M
    Pedrinis, E
    Agazzi, A
    Zucca, E
    BLOOD, 2003, 102 (11) : 410A - 410A
  • [4] Systemic therapy of primary cutaneous B-cell lymphoma, marginal zone type, with Rituximab, a chimeric Anti-CD20 monoclonal antibody
    Soda, R
    Costanzo, A
    Cantonetti, M
    Orlandi, A
    Bianchi, L
    Chimenti, S
    ACTA DERMATO-VENEREOLOGICA, 2001, 81 (03) : 207 - 208
  • [5] Anti-CD20 monoclonal antibody therapy in relapsed MALT lymphoma of the conjunctiva
    Nückel, H
    Meller, D
    Steuhl, KP
    Dührsen, U
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2004, 73 (04) : 258 - 262
  • [6] Mechanism of action on B cell lymphoma by chimeric anti-CD20 monoclonal antibody
    T Oyama
    Y Kagami
    M Seto
    Y Morishima
    Leukemia, 2001, 15 : 1667 - 1667
  • [7] Mechanism of action on B cell lymphoma by chimeric anti-CD20 monoclonal antibody
    Oyama, T
    Kagami, Y
    Seto, M
    Morishima, Y
    LEUKEMIA, 2001, 15 (10) : 1667 - 1667
  • [8] Anti-CD20 monoclonal antibody therapy for non-Hodgkin's lymphoma
    White, CA
    Weaver, R
    Royston, I
    MINERVA BIOTECNOLOGICA, 1998, 10 (03) : 108 - 116
  • [9] Anti-lymphoma activity of a new humanized anti-CD20 monoclonal antibody, hA20
    Goldenberg, DM
    On, ZX
    Horak, ID
    Hansen, H
    Stein, R
    FASEB JOURNAL, 2003, 17 (07): : C123 - C123
  • [10] Effects of combined therapy with gemcitabine and the anti-CD20 monoclonal antibody rituximab on human lymphoma cell lines.
    Joshi, I
    Jin, F
    Obasaju, C
    Smith, MR
    BLOOD, 2002, 100 (11) : 308B - 308B
12345